Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?

PubWeight™: 0.79‹?›

🔗 View Article (PMID 21532939)

Published in Expert Opin Drug Discov on February 01, 2011

Authors

David J Riese1

Author Affiliations

1: George Fulton Gilliland & Olga Hooser Gilliland Franklin Professor, Associate Dean for Research and Graduate Programs, Auburn University Harrison School of Pharmacy, 2316 Walker Building, Auburn, AL 36849-5501.

Associated clinical trials:

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (CLEOPATRA) (CLEOPATRA) | NCT00567190

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE) | NCT01120184